ADVERSE REACTIONS SECTION.

ADVERSE REACTIONS. To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-877-845-0689 or FDA at 1-800-332-1088 or www.fda.gov/medwatch.1-800-FDA-1088.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL.

PRINCIPAL DISPLAY PANEL. NDC 0143-9141-01 Rx onlyDOBUTamineInjection, USP250 mg per 20 mL (12.5 mg/mL)For Intravenous Use ONLYMust be diluted prior to useUse within 24 hours after dilution20 mL Single-Dose VialNDC 0143-9141-10 Rx onlyDOBUTamineInjection, USP250 mg per 20 mL (12.5 mg/mL)For Intravenous Use ONLYMust be diluted prior to useUse within 24 hours after dilution10 20 mL Single-Dose Vials. vial label. carton label.